LOCAL CONTROL MODALITY AND OUTCOME IN EWING SARCOMA OF THE FEMUR: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP Najat C. Daw, Nadia N. Laack, Elizabeth J.

Slides:



Advertisements
Similar presentations
Oncologic Drugs Advisory Committee
Advertisements

Treatment of Relapsed Osteosarcoma After Contemporary Therapy: The Memorial Sloan-Kettering Experience Chou AJ, Merola PR, Vyas Y, Wexler L, Gorlick R,
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
CARBON ION THERAPY FOR SACRAL CHORDOMAS
Danny Indelicato, MD CTOS 2012 Ewing Sarcoma of the Axial Skeleton: Early Outcomes from the University of Florida Proton Therapy Program.
Primary thoracic sarcomas: prognostic factors and outcome in a series of patients treated at a single institution Leonardo Duranti T horacic Surgery.
Children’s Oncology Group Sarcoma Plans Holcombe E. Grier MD For the Children’s Oncology Group.
Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD.
Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.
Value of local treatment in extrapulmonary metastatic Ewing sarcoma
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
Faculty of Medical Science, Stip and Clinic of Oncology and Radiotherapy, Skopje R.Macedonia Ewing sarcoma: a case report D-r Marija Karakolevska - Ilova.
Non-metastatic Osteosarcoma: Response based augmentatation of therapy P9754 A Children’s Oncology Group Study Schwartz CL, Wexler LH, Devidas M, Teot LA,
Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.
LOCAL CONTROL AMONG YOUNG PATIENTS WITH NON-RHABDOMYOSARCOMA SOFT TISSUE SARCOMA (NRSTS) FOLLOWING RISK-BASED TREATMENT: RESULTS FROM CHILDREN’S ONCOLOGY.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Targeting Tumors Using Endogenous Albumin
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
BONE CANCER RAED ISSOU.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.
CTOS: A Herman Suit Legacy Michael A. Simon, MD The University of Chicago.
Challenges in the Treating of Bone and Soft Tissue Sarcomas Margaret von Mehren, MD Director Sarcoma Oncology Fox Chase Cancer Center Philadelphia, PA.
Clinical features and outcome in ovarian sarcomas: Analysis of a single-institution experience A López Pousa, X Gonzàlez Farré, MJ. Quintana, S Bagué,
Intergroup trial CALGB 80101
Clinical Outcomes and Patterns of Failure in Pineoblastoma: A 30-year Single Institution Experience Benjamin Farnia, B.A. ASTRO Poster Discussion September.
Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,
SPINDLE CELL SARCOMA OF BONE AN ASSESSMENT OF OUTCOME
Up-Front Phase II Windows in Children with Cancer Victor M. Santana, M.D.
Devin schonewolf Biology 2 mcgarvey
End of Life Decisions by Adults with Cancer : Role of Religious Practices and Spiritual Beliefs Rudolph M. Navari, M.D., Ph.D. Assistant Dean and Director.
Quantitative Dosimetric Analysis Of Patterns Of Local Relapse After IMRT For Primary Extremity Soft Tissue Sarcomas Ryan M. Lanning, Sean L. Berry, Michael.
A systematic meta-analysis of randomized controlled trials for adjuvant chemotherapy for localized resectable soft-tissue sarcoma Nabeel Pervaiz Nigel.
Adductor Compartment STS - Does method of treatment affect outcome? Anup Pradhan, Yiu-Chung Cheung Birmingham Medical School, UK Supervisors: Mr Robert.
HCI Sarcoma Services Sequential Dependency of Radiotherapy for Soft-Tissue Sarcoma S Sampath TE Schultheiss YJ Hitchcock RL Randall DC Shrieve JYC Wong.
IMPROVED OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SOFT-TISSUE OR BONE SARCOMAS WHO ACHIEVED A CLINICAL-BENEFIT RESPONSE WHEN TREATED WITH AP23573, A.
Local Control for Intermediate Risk Rhabdomyosarcoma: Results from D9803 according to Histology, Group, Site and Size A Report from the Children’s.
Change in Anatomic Distribution of Relapses with Accelerated Chemotherapy in Ewing Sarcoma RB Womer, AR Weiss, DC West, MD Krailo, PS Dickman, B Pawel,
Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.
Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.
EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.
Per-Ulf Tunn, D. Andreou, S. Fehlberg, M. Werner, P. Reichardt
Phase III Study of Concurrent Chemotherapy and Radiotherapy (CT/RT) versus CT/RT followed by Surgical Resection for Stage IIIA(pN2) NSCLC Outcomes Update.
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
Introduction Osteosarcoma is the most common primary bone tumor diagnosed in childhood and adolescence, with peak incidence from ages 12-16; overall survival.
CTOS, Berlin 2014 The influence of time interval between preoperative radiation and surgical resection on the development of wound healing complications.
Aggressive extra-abdominal fibromatosis: can aggressive management be avoided in a subgroup of patients ? S. Bonvalot *, H. Eldweny *, V Haddad A. Le Cesne,
Correlation of Hand-Foot Skin Reaction (HFS) with Treatment Efficacy in Pancreatic Cancer (PC) Patients (pts) Treated with Gemcitabine/Capecitabine plus.
Hypofractionated vs. Standard Radiotherapy with or without Temozolomide for Older Patients with Glioblastoma Shyam K. Tanguturi MD, Ayal A. Aizer MD MHS,
J. Lujan, G. Valero, Q. Hernandez, A. Sanchez, M.D. Frutos and P. Parrilla. British Journal of Surgery, September 2009.
The Royal Marsden Solitary fibrous tumours The outcomes of 106 patients illustrating the unpredictable biological behaviour N Alexander, K Thway, JM Thomas,
Ongoing collaborative projects Prospective for collaborative projects Kirsten Sundby Hall Oslo CTOS 4. Nov - 06.
1 Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival: A report from the Children’s Oncology Group Paul A. Meyers,
National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.
Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.
Pt ZJ 19yo M that presented to Seattle Children’s for evaluation of 3 lesions found on recent PET CT ◦ One large mass in the posterior mediastinum just.
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Perioperative Complications after Neoadjuvant Chemoradiation for Locally-Advanced Esophageal Cancer: A Comparison of Platinum/5-FU and Carboplatin/Paclitaxel.
Ewing sarcoma of the ribResults of an intergroup study with analysis of outcome by timing of resection  Robert C. Shamberger, MD, FACS, Michael P. LaQuaglia,
Results of Definitive Radiotherapy in Anal Canal Carcinoma
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
MC BROWNa, MS PEARCEa, J SALOTTIa, AW CRAFTb, J HALEb
Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.
ACT II: The Second UK Phase III Anal Cancer Trial
Gordon LI et al. Proc ASH 2010;Abstract 415.
Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemoradiotherapy for locally advanced rectal cancer: safety results of a randomized phase III.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Ewing sarcoma of the ribResults of an intergroup study with analysis of outcome by timing of resection  Robert C. Shamberger, MD, FACS, Michael P. LaQuaglia,
Presentation transcript:

LOCAL CONTROL MODALITY AND OUTCOME IN EWING SARCOMA OF THE FEMUR: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP Najat C. Daw, Nadia N. Laack, Elizabeth J. McIlvaine, Mark Krailo, Richard B. Womer, Linda Granowetter, Holcombe E. Grier, Neyssa M. Marina, Mark L. Bernstein, Richard G. Gorlick, R. Lor Randall CTOS 2014, Berlin Germany

The femur is the most frequently involved bone by Ewing sarcoma and has the greatest structural significance. Reported 5-year overall survival for localized disease 31% - 64%. Survival of patients treated with surgery with or without radiotherapy is better than that of patients treated with radiotherapy alone. Local control modality at this site is controversial. Background

To describe the treatment and outcome of patients with localized Ewing sarcoma of the femur treated on 3 consecutive cooperative group trials To determine the effect of local control modality on tumor local control and patient outcome Study Objectives

Review of patients with localized Ewing sarcoma of femur treated on INT-0091, INT-0154, and AEWS0031. Included only patients who received vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide (VDC/IE) every 3 weeks and local therapy after neoadjuvant chemotherapy. Analysis of disease outcome in relation to local control modality: surgery, surgery plus radiotherapy (RT), RT. Differences in survival curves were assessed using log- rank tests. Cumulative incidence was calculated using the method of Fine. Patients and Methods

Results CharacteristicNo. of patients% Median age in yr (range)13 (1-33) Gender Male Female % 40% Race Caucasian Black Latino/Hispanic Other Missing % 4% 9% 1% 2% Location in femur Proximal Mid Distal Unknown % 23% 17% 18% Tumor size > 8 cm ≤ 8 cm Not reported % 23% 52% 131 patients with localized EWS of femur identified 16 excluded for incomplete data on local control 115 had complete data on local control

Treatment N% Treatment regimen INT-0091 experimental arm INT-0154 standard arm AEWS0031 standard arm % 44% 28% Local control modality Surgery only Surgery + RT RT only % 15% 12% Type of surgery/reconstruction (n=101) Amputation Prosthesis/allograft prosthetic composite Allograft Vascularized autograft Rotationplasty Unknown % 35% 37% 7% 2% 15%

Patient Outcome (N=115) 5-yr EFS 65%, 95% CI (55%, 73%) 5-yr OS 70%, 95% CI (61%, 78%)

Event-Free Survival by Tumor Size

EFS by Local Control Modality

Overall Survival by Local Control Modality

Cumulative Incidence of Local Failure not Associated with Type of Local Control p=0.57

Ewing sarcoma of the femur arises most commonly in the proximal aspect of the bone. Most common local treatment was surgery alone. Patients treated with VDC/IE every 3 weeks appear to have an EFS comparable to that of patients with Ewing sarcoma in general. The local control modality did not significantly affect disease outcome. Further study of treatment complications and functional outcome of the limb is needed to determine the optimal local control modality. Conclusions

COG Bone Sarcoma Committee members Treating physicians/investigators and CRAs at participating sites Participating patients and their families Acknowledgements

Outcome by Surgery vs Any RT EFS Overall Survival